Colesevelam HCl: a non-systemic lipidaltering drug

Bibliography

• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• ••A summary of recommendations ofcholesterol treatment goals from an expert panel.
   Google Scholar
• The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid research clinics program. JAMA (1984) 251:351–364.
   Google Scholar
• ••One of the classic, landmark outcomestudies involving resin therapy.
   Google Scholar
• GOTTO AM: Contemporary diagnosis and management of lipid disorders, 2m edri (1999–2000). Handbooks in Healthcare Co.
   Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RL, SANMARCO ME, AZEN SP, CASHIN-HEMPHILL L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 257(23):3233–3240.
   PubMed Web of Science ®Google Scholar
• CASHIN-HEMPHILL L, MACK WJ, POGODA JM, SANMARCO ME, AZEN SP, BLAKENHORN DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4 year follow-up. JAMA 264(23):3013–3017.
   Google Scholar
• ••Another classic, landmark outcome studyinvolving resin therapy.
   Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl. j. Med. (2001) 345(22):1583–1592.
   PubMed Web of Science ®Google Scholar
• KANE JP, MALLOY MJ, PORTS TA, PHILLIPS NR, DIEHL JC, HAVEL RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drugregimens. JAMA (1990) 264: 3007–3012.
   PubMed Web of Science ®Google Scholar
• DONOVAN JM, STYPINSKI D, STILES MR, OLSON TA, BURKE SK: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther. (2000) 14:681–690.
   PubMed Web of Science ®Google Scholar
• HEIDELBAUGH JJ, RION RJ: Diagnosis and management of lipid disorders. Chu. Fain. Pict. (2001) 3(4):757–780.
   Google Scholar
• NEZASA K, TADAO A, KIMURA K, TAKAICHI M, INAZAWA K, KOIKE M: Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in rat. Xerrobiotica (2002) 32(8):715–727.
   PubMed Web of Science ®Google Scholar
• BAYS HE, DUJOVNE CA: Drug interactions of lipid-altering drugs. Drug Sat: (1998) 19(5):355–371.
   PubMed Web of Science ®Google Scholar
• THOMPSON PD, CLARKSON P, KARAS RH: Statin-associated myopathy. JAMA (2003) 289:1681–1690.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163:553–564.
   PubMed Web of Science ®Google Scholar
• BAYS HE: Ezetimibe. Expert Opin. Investig. Drugs (2002) 11(11):1587–1604.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of ezetimibe.
   Google Scholar
• ALDRIDGE MA, MATTHEW KI: Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. (2001) 35:898–907.
   PubMed Web of Science ®Google Scholar
• DIETS CHY JM: Theoretical considerations of what regulates low density lipoprotein and high density lipoprotein cholesterol. Am. J. Clin. Nutr. (1997) 65\(Suppl. 5):1581S–1589S.
   Google Scholar
• •Discusses the concepts of cholesterol regulation.
   Google Scholar
• SPADY DK, DIETSCHY JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J. Lipid Res. (1983) 24:303–315.
   PubMed Web of Science ®Google Scholar
• ••Interesting findings regarding the relativecholesterol production in various organs.
   Google Scholar
• DIETSCHY JM, TURLEY SD, SPADY DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. (1993) 34(10):1637–1659.
   PubMed Web of Science ®Google Scholar
• BAYS HE: Existing and investigational combination drug therapy for high-density lipoprotein cholesterol Am. J. Cordial. (2002) 90(Suppl.):30K–43K.
   Google Scholar
• •A review of the importance of HDL-C as a therapeutic target to reduce CHD.
   Google Scholar
• JOLLEY CD, WOOLLETT LA, TURLEY SD, DIETSCHY JM: Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-1 concentration. J. Lipid Res. (1998) 39:2143–2149.
   PubMed Web of Science ®Google Scholar
• HELLER DP, BURKE SK, DAVIDSON DM, DONOVAN JM: Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother. (2002) 36:398–403.
   PubMed Web of Science ®Google Scholar
• STEINMETZ KL: Colesevelam hydrochloride. Am J. Health-Syst. Pharm. (2002) 59:932–939.
   PubMed Web of Science ®Google Scholar
• DAVISDSON MH, DILLON MA, GORDON B etal.: Colesevelam hydrochloride (Cholestagefl: a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893–1900.
   Google Scholar
• •Another review of colesevelam.
   Google Scholar
• AVORN J, MONETTE J, LACOUR A et al.:Persistence of use of lipid-lowering medications: a cross national study. JAMA (1998) 279(18): 1458–1462.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RM: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin. Investig. Drugs (2000) 9(11):2663–2671.
   PubMed Web of Science ®Google Scholar
• HUNNINGHAKE D, INSULL W TOTH E DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158:407–416.
   PubMed Web of Science ®Google Scholar
• KNAPP HH, SCHROTT H, MAP etal.: Safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352–360.
   Google Scholar
• BAYS HE, WEISS S, GAGNE C et al: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral contributions. J. Am. Coll. Cordial. (2002) 39(Suppl. 5A):833–834.
   Google Scholar
• GAGNE C, BAYS HE, WEISS SR et al: For the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J.Cardial. (2002) 90(10):1084.
   Google Scholar
• •A model trial to determine the lipid effects of adding a GI-acting, lipid-altering drug to patients whose lipid blood levels were stabilised on statin therapy.
   Google Scholar
• MCKENNEY J: Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. Am. J. Cordial. (2002) 90(10B):8K–20K.
   Google Scholar
• GRUNDY SM: Alternative approaches to cholesterol-lowering therapy. Am. J. Cordial. (2002) 90(10):1135–1138.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH: Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cordial. (2002) 90(10B):50K–60K.
   Google Scholar
• DUJOVNE CA: Side effects of statins: hepatitis versus transaminitis' myositis versus CPKitis'. Am. J. Cordial (2002) 89(12):1411–1413.
   PubMed Web of Science ®Google Scholar
• PHILLIPS PS, HAAS RH, BANNYKH S et al.: The scripps mercy clinical research center statin-associated myopathy with normal creatine kinase levels Ann. Intern. Med. (2002) 137:581–585.
   Google Scholar
• GRUNDY SM: Can statins cause chronic low-grade myopathy? Ann. Intern. Med. (2002) 137:617–618.
   Web of Science ®Google Scholar
• BAYS HE, DUJOVNE CA, MCGOVERN ME etal.: Comparison of once-daily, niacin extended-releasehovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE)). Am. J. Cordial (2003) 91:667–672.
   Google Scholar
• INSULL W, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized control trial. Mayo Clin. Proc. (2001) 76(10):971–982.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MET, DILLON MA, GORDON B etal.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159(16):1893–1900.
   Google Scholar